Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 12/20 | 0.40 |
| ▸ | RAB9A | P51151 | 12/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131484 | 0.89 | TP53 (0.47) | NPC1RAB9AMEN1KMT2ATP53 | |
| SCHEMBL4125446 | 0.86 | TP53 (0.48) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4141295 | 0.85 | NPC1 (0.40) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4136995 | 0.85 | NPC1 (0.45) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4134769 | 0.84 | TP53 (0.46) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4426009 | 0.82 | TP53 (0.48) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4137314 | 0.82 | DYRK3 (0.44) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4130870 | 0.82 | TP53 (0.46) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4140017 | 0.81 | NPC1 (0.43) | NPC1RAB9APAX8MEN1HSP90AA1 | |
| SCHEMBL4125567 | 0.81 | NPC1 (0.40) | NPC1RAB9APAX8MEN1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021004-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2009-02-11 | — | — | EP | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | claimed |
| WO-2007133561-A2 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | claimed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | WDR5 1151/4885NPC1 2854/4885RAB9A 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.